AVROBIO INC's ticker is AVRO and the CUSIP is 05455M100. A total of 100 filers reported holding AVROBIO INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $364,364 | +49.1% | 236,600 | -8.0% | 0.00% | 0.0% |
| Q2 2023 | $244,366 | -26.4% | 257,200 | -22.6% | 0.00% | 0.0% |
| Q1 2023 | $332,100 | +36.3% | 332,100 | -2.8% | 0.00% | 0.0% |
| Q4 2022 | $243,669 | -3.3% | 341,800 | -12.9% | 0.00% | 0.0% |
| Q3 2022 | $252,000 | -51.8% | 392,200 | -31.0% | 0.00% | 0.0% |
| Q2 2022 | $523,000 | -41.4% | 568,000 | -16.0% | 0.00% | -50.0% |
| Q1 2022 | $892,000 | -44.0% | 675,800 | +63.3% | 0.00% | -50.0% |
| Q4 2021 | $1,593,000 | +0.1% | 413,800 | +45.0% | 0.00% | 0.0% |
| Q3 2021 | $1,592,000 | +131.4% | 285,300 | +268.6% | 0.00% | +100.0% |
| Q2 2021 | $688,000 | -41.9% | 77,400 | -17.1% | 0.00% | -33.3% |
| Q1 2021 | $1,185,000 | +47.8% | 93,400 | +62.4% | 0.00% | +50.0% |
| Q4 2020 | $802,000 | +311.3% | 57,500 | +283.3% | 0.00% | +100.0% |
| Q3 2020 | $195,000 | -29.6% | 15,000 | -5.7% | 0.00% | 0.0% |
| Q2 2020 | $277,000 | – | 15,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 4,520,863 | $5,968,000 | 0.76% |
| Aisling Capital Management LP | 1,009,779 | $1,333,000 | 0.72% |
| MPM BioImpact LLC | 647,918 | $855,000 | 0.23% |
| GMT CAPITAL CORP | 2,594,914 | $3,425,000 | 0.22% |
| New Leaf Venture Partners, L.L.C. | 315,550 | $417,000 | 0.21% |
| GSA CAPITAL PARTNERS LLP | 338,422 | $447,000 | 0.06% |
| Penn Mutual Asset Management, LLC | 37,306 | $49,000 | 0.06% |
| Eversept Partners, LP | 295,369 | $389,887 | 0.03% |
| XTX Topco Ltd | 23,289 | $31,000 | 0.01% |
| Colonial River Wealth Management, LLC | 17,636 | $23,000 | 0.01% |